RxDoctor Payments Data

Miguel Rebollar

Internal Medicine · Hialeah, FLNPI 1831108729

Payments from drug & device makers

$548,157in general payments, 2019–2025

Across 235 payments — averaging $2332.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$388K
  • Novo Nordisk AS$155K
  • Esperion Therapeutics, Inc.$916
  • Novartis$528
  • Amgen$493
  • AbbVie$481
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$5,133100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$548,157 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol82$58,370
EliquisApixaban54$35,367
OzempicSemaglutide33$33,702
MounjaroTirzepatide21$24,770
JanuviaSitagliptin Phosphate23$23,863
JardianceEmpagliflozin13$18,481
JanumetSitagliptin Phos/Metformin Hcl13$18,436
LinzessLinaclotide32$17,490
EntrestoSacubitril/Valsartan22$16,467
MyrbetriqMirabegron20$8,994
Tadalafil30$8,967
CreonLipase/Protease/Amylase18$7,707
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,446
LumiganBimatoprost13$4,199
LivaloPitavastatin Calcium13$4,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$130$58,37082 claims
Novo NordiskOzempic$116$33,70233 claims
AbbVieLinzess, Creon, Lumigan$481$29,39763 claims
Lilly USA, LLCMounjaro$265$24,77021 claims
NovartisEntresto$528$16,46722 claims
Astellas Pharma US IncMyrbetriq$112$8,99420 claims
Kowa Pharmaceuticals America, Inc.Livalo$20$4,08913 claims
Sanofi-aventis U.S. LLCLantus$247$1,98828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →